Determinants for Simultaneous Binding of Copper and Platinum to Human Chaperone Atox1: Hitchhiking not Hijacking

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Palm Espling, Maria E ^a   Andersson, C David ^a   Björn, Erik ^a   Linusson, Anna ^a   Wittung Stafshede, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CISPLATIN; COPPER ION; DIMER; MENKES PROTEIN; MONOMER; OLIGOMER; PROTEIN ATOX1; PROTEIN VARIANT; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

ARTICLE; CIRCULAR DICHROISM; COMPLEX FORMATION; COMPUTER MODEL; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DETOXIFICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; ION TRANSPORT; MOLECULAR INTERACTION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TRANSPORT; PROTEIN UNFOLDING;

BINDING SITES; COPPER; HUMANS; METALLOCHAPERONES; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; PLATINUM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN UNFOLDING;

EID: 84880802908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070473     Document Type: Article

References (53)

1. Köberle B, Tomicic MT, Usanova S, Kaina B, (2010) Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta, Rev Cancer 1806: 172-182.
2. Wheate NJ, Walker S, Craig GE, Oun R, (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39: 8113-8127.
3. Shen D-W, Pouliot LM, Hall MD, Gottesman MM, (2012) Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64: 706-721.
4. Howell SB, Safaei R, Larson CA, Sailor MJ, (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77: 887-894.
5. Holzer AK, Howell SB, (2006) The internalization and degradation of human copper transporter 1 following Cisplatin exposure. Cancer Res 66: 10944-10952.
6. Liang ZD, Long Y, Tsai W-B, Fu S, Kurzrock R, et al. (2012) Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Therap 11: 2483-2494.
7. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, et al. (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to Cisplatin, Carboplatin, and Oxaliplatin in ovarian cancer cells. Clin Cancer Res 10: 4661-4669.
8. Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, et al. (2004) Confocal microscopic analysis of the interaction between Cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 10: 4578-4588.
9. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, et al. (2002) Acquisition of resistance to Cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565.
10. Komatsu M, Sumizawa T, Mutoh M, Chen Z-S, Terada K, et al. (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with Cisplatin resistance. Cancer Res 60: 1312-1316.
11. Banci L, Bertini I, Cantini F, Rosenzweig AC, Yatsunyk LA, (2008) Metal binding domains 3 and 4 of the Wilson disease protein: Solution structure and interaction with the copper(I) chaperone HAH1. Biochem 47: 7423-7429.
12. Arnesano F, Banci L, Bertini I, Ciofi-Baffoni S, Molteni E, et al. (2002) Metallochaperones and metal-transporting ATPases: a comparative analysis of sequences and structures. Genome Res 12: 255-271.
13. Palm ME, Weise CF, Lundin C, Wingsle G, Nygren Y, et al. (2011) Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. Proc Natl Acad Sci U S A 108: 6951-6956.
14. Dolgova NV, Olson D, Lutsenko S, Dmitriev OY, (2009) The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies Cisplatin. Biochem J 419: 51-56.
15. Safaei R, Adams PL, Maktabi MH, Mathews RA, Howell SB, (2012) The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J Inorg Biochem 110: 8-17.
16. Anastassopoulou I, Banci L, Bertini I, Cantini F, Katsari E, et al. (2004) Solution structure of the apo and copper(I)-loaded human metallochaperone HAH1. Biochem 43: 13046-13053.
17. Boal AK, Rosenzweig AC, (2009) Crystal structures of cisplatin bound to a human copper chaperone. J Am Chem Soc 131: 14196-14197.
18. Arnesano F, Banci L, Bertini I, Felli IC, Losacco M, et al. (2011) Probing the interaction of Cisplatin with the human copper chaperone Atox1 by solution and in-cell NMR spectroscopy. J Am Chem Soc 133: 18361-18369.
19. Hua H, Günther V, Georgiev O, Schaffner W, (2011) Distorted copper homeostasis with decreased sensitivity to cisplatin upon chaperone Atox1 deletion in Drosophila. BioMetals 24: 445-453.
20. Safaei R, Maktabi MH, Blair BG, Larson CA, Howell SB, (2009) Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. J Inorg Biochem 103: 333-341.
21. Palm-Espling ME, Wittung-Stafshede P, (2012) Reaction of platinum anticancer drugs and drug derivatives with a copper transporting protein, Atox1. Biochem Pharmacol 83: 874-881.
22. Moret M-E, Chen P, (2008) Mononuclear Organometallic Platinum(II) Complexes and Platinum(II)-Copper(I) Mixed Complexes from Symmetrical 3,5-Bis(iminoacetyl)pyrazolate Ligands. Organometallics 27: 4903-4916.
23. Moret M-E, Serra D, Bach A, Chen P, (2010) Transmetalation supported by a PtII CuI bond. Angew Chem Int Ed 49: 2873-2877.
24. Fusch G, Fusch EC, Erxleben A, Hüttermann J, Scholl H-J, et al. (1996) Heteronuclear μ-1-methylcytosinato-N3,N4 complexes containing very short Pt → Cu dative bonds. Inorg Chim Acta 252: 167-178.
25. Guo Z (2009) Room temperature tunable energy transfer systems in different solvents. Thesis, The University of Maine.
26. Lindahl PA, (2012) Metal-metal bonds in biology. J Inorg Biochem 106: 172-178.
27. Kihlken MA, Leech AP, Le Brun NE, (2002) Copper-mediated dimerization of CopZ, a predicted copper chaperone from Bacillus subtilis. Biochem J 368: 729-739.
28. Hussain F, Rodriguez-Granillo A, Wittung-Stafshede P, (2009) Lysine-60 in copper chaperone atox1 plays an essential role in adduct formation with a target Wilson disease domain. J Am Chem Soc 131: 16371-16373.
29. Niemiec MS, Weise CF, Wittung-Stafshede P, (2012) In vitro thermodynamic dissection of human copper transfer from chaperone to target protein. PLoS ONE 7: e36102.
30. TURBOMOLE V6.3.1 2012, University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, 1989-2007, TURBOMOLE GmbH, since 2007; available from www.turbomole.com.Accessed 2013 Jun 28.
31. Grimme S, Antony J, Ehrlich S, Krieg H, (2010) A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys 132: 154104-154119.
32. Ahlrichs R, Bär M, Häser M, Horn H, Kölmel C, (1989) Electronic structure calculations on workstation computers: The program system turbomole. Chem Phys Lett 162: 165-169.
33. Schafer A, Horn H, Ahlrichs R, (1992) Fully optimized contracted Gaussian basis sets for atoms Li to Kr. J Chem Phys 97: 2571-2577.
34. Weigend F, Ahlrichs R, (2005) Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. Phys Chem Chemical Physics 7: 3297-3305.
35. Figgen D, Rauhut G, Dolg M, Stoll H, (2005) Energy-consistent pseudopotentials for group 11 and 12 atoms: adjustment to multi-configuration Dirac-Hartree-Fock data. Chem Phys 311: 227-244.
36. Alvarez HM, Xue Y, Robinson CD, Canalizo-Hernandez MA, Marvin RG, et al. (2009) Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation. Science.
37. Banci L, Bertini I, Cantini F, Felli IC, Gonnelli L, et al. (2006) The Atx1-Ccc2 complex is a metal-mediated protein-protein interaction. Nat Chem Biol 2: 367-368.
38. Hussain F, Wittung-Stafshede P, (2007) Impact of cofactor on stability of bacterial (CopZ) and human (Atox1) copper chaperones. Biochim Biophys Acta, Prot & Proteom 1774: 1316-1322.
39. Sreerama N, Woody RW (2000) Circular dichroism of peptides and proteins. In: Nina B, Koji N, W WR, editors. Circular Dichroism: Principles and Applications: Wiley-VCH Ink.
40. Rodriguez-Granillo A, Wittung-Stafshede P, (2009) Differential roles of Met10, Thr11, and Lys60 in structural dynamics of human copper chaperone Atox1. Biochem 48: 960-972.
41. Wernimont AK, Huffman DL, Lamb AL, O'Halloran TV, Rosenzweig AC, (2000) Structural basis for copper transfer by the metallochaperone for the Menkes/Wilson disease proteins. Nat Struct Mol Biol 7: 766-771.
42. Moret M-E, Chen P, (2008) Mononuclear organometallic platinum(II) complexes and platinum(II)-copper(I) mixed complexes from symmetrical 3,5-Bis(iminoacetyl)pyrazolate ligands. Organometal 27: 4903-4916.
43. Wing-Wah Yam V, Yu K-L, Cheung K-K, (1999) Luminescence and aggregation studies of hexanuclear platinum-copper acetylide complexes. Crystal structure of the luminescent metal-metal bonded dimer [Pt2Cu4(C[triple bond, length half m-dash]CPh)8]2. J Chem Soc, Dalton Trans 0: 2913-2915.
44. Xia B-H, Zhang H-X, Che C-M, Leung K-H, Phillips DL, et al. (2003) Metal-metal interactions in heterobimetallic d8-d10 complexes. Structures and spectroscopic investigation of [M'M" (μ-dcpm)2(CN)2]+ (M' = Pt, Pd; M" = Cu, Ag, Au) and related complexes by UV-vis absorption and resonance raman spectroscopy and ab initio calculations. J Am Chem Soc 125: 10362-10374.
45. Banks CV, Barnum DW, (1958) Intermolecular metal-metal bonds and absorption spectra of some Nickel(II) and Palladium(II) complexes of vic-dioximes1. J Am Chem Soc 80: 4767-4772.
46. Lewis J, (1965) Metal-metal interaction in transition metal complexes. Pure Appl Chem 10: 11-36.
47. Hermann G, Heffeter P, Falta T, Berger W, Hann S, et al. (2013) In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS. Metallomics.
48. Tippayamontri T, Kotb R, Paquette B, Sanche L, (2011) Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Investig New Drugs 29: 1321-1327.
49. Arnesano F, Scintilla S, Natile G, (2007) Interaction between platinum complexes and a methionine motif found in copper transport proteins. Angew Chem Int Ed 46: 9062-9064.
50. Wu Z, Liu Q, Liang X, Yang X, Wang N, et al. (2009) Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1. J Biol Inorg Chem 14: 1313-1323.
51. Calderone V, Casini A, Mangani S, Messori L, Orioli PL, (2006) Structural investigation of cisplatin-protein interactions: selective platination of His19 in a cuprozinc superoxide dismutase. Angew Chem Int Ed Engl 45: 1267-1269.
52. Casini A, Mastrobuoni G, Temperini C, Gabbiani C, Francese S, et al. (2007) ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb): 156-158.
53. Gabbiani C, Scaletti F, Massai L, Michelucci E, Cinellu MA, et al. (2012) Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. Chem Commun 48: 11623-11625.